Why ARK Genomic Revolution ETF (ARKG) Is Up +32% in the Last 30 Days
Key Takeaways
- ARKG advanced roughly 32% over the trailing 30 days, extending a powerful genomics and precision-medicine rally.
- The fund has climbed about 56% over the past three months, led by AI-driven drug discovery and strong diagnostics earnings.
- A late-period catalyst came from positive Phase III data for an individualized mRNA cancer therapy, which lifted the broader biotech complex.
- Top holdings TWST and TEM were among the largest contributors, supported by AI protein-design momentum and a first GAAP profit.
- ARKG remains a concentrated, actively managed, healthcare-heavy thematic ETF, which magnifies both upside and downside.
ARK Genomic Revolution ETF (ARKG) Overview and Portfolio Exposure
The ARK Genomic Revolution ETF (ARKG) is an actively managed, non-diversified thematic exchange-traded fund that seeks long-term growth of capital. Under normal circumstances it invests at least 80% of its assets in companies relevant to the genomics revolution, spanning healthcare, information technology, materials, energy, and consumer discretionary. The fund charges a net expense ratio of 0.75% and typically holds roughly 31 positions, with assets under management (AUM) in the range of roughly $1.8 billion.
The portfolio is overwhelmingly healthcare-oriented, with approximately 99% of holdings allocated to the healthcare sector and about 90% in U.S.-listed equities. Its largest positions include TEM (Tempus AI), TWST (Twist Bioscience), CRSP (CRISPR Therapeutics), TXG (10x Genomics), BEAM (Beam Therapeutics), ABSI (Absci), NTRA (Natera), ILMN (Illumina), NTLA (Intellia Therapeutics), and PSNL (Personalis), with the top 10 names representing a substantial majority of total assets. This concentration means a handful of high-beta, innovation-driven stocks can dominate the ETF's short-term performance.
ARK Genomic Revolution ETF (ARKG) Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, ARKG rose from roughly $37.79 to about $50.06, an increase of approximately 32%. The move was not gradual; it accelerated sharply in the final stretch, reflecting a trend-driven breakout rather than steady accumulation. Over the trailing three months, the fund advanced roughly 56%, rising from about $32.06 to the current level, confirming a broader upward trajectory. On a year-to-date basis the fund has gained close to 50%, underscoring a multi-month rotation back into genomics after years of underperformance.
What Drove ARKG Price in the Last 30 Days
The 30-day surge was powered primarily by the fund's largest holdings. TWST (Twist Bioscience) rallied after reporting fiscal third-quarter revenue of about $118 million, up 23% year over year, marking a fourteenth consecutive quarter of sequential growth, with AI drug-discovery revenue up sharply. The stock gained further after being selected as an independent evaluator for an AI-designed protein-binding campaign, reinforcing investor enthusiasm for the convergence of artificial intelligence and drug design.
TEM (Tempus AI) also surged after posting its first GAAP profit, a sizable revenue beat, and raised full-year guidance, with elevated short interest amplifying the move. A decisive catalyst arrived in mid-August, when MRNA (Moderna) and MRK (Merck) announced that a Phase III trial of an individualized mRNA cancer therapy met its primary and secondary endpoints, sending Moderna shares up sharply and lifting the entire biotech complex; ARKG gained about 10.5% in a single session. Strength in TXG (10x Genomics), NTRA (Natera), and GH (Guardant Health) contributed further upside.
What Drove ARKG Performance Over the Last Quarter
The three-month advance reflects a broader sector rotation into precision medicine and AI-enabled drug discovery, rather than a single event. Sequencing and diagnostics leaders delivered repeated earnings beats, while the "AI plus genomics" narrative drew institutional capital back into a theme that had languished for years. The rally was reinforced by strength in DNA-synthesis and gene-editing names, improving sentiment around clinical data readouts, and a favorable environment for high-growth healthcare innovation. The concentration of ARKG in a small number of rapidly appreciating holdings amplified the fund's quarterly return relative to more diversified healthcare benchmarks.
AI Screener
Tickeron's AI Screener is an AI-powered stock and ETF discovery platform that helps investors scan thousands of securities using technical indicators, fundamentals, volatility metrics, price patterns, industry filters, AI-generated signals, and performance characteristics. The tool is designed to surface trending names, breakout candidates, and emerging opportunities far more efficiently than manual screening, making it a useful companion for investors monitoring fast-moving thematic areas such as genomics and biotechnology. Traders and analysts can use it to filter by sector, momentum, and technical setup to build watchlists aligned with current market trends.
ARKG ETF Outlook: What Investors Should Watch Next
Looking ahead, the most important factors for ARKG include continued earnings execution from its largest holdings, the pace of AI-drug-discovery commercialization, and upcoming clinical trial readouts across its gene-editing and diagnostics names. Interest rate expectations and inflation trends will also matter, given the sensitivity of long-duration, high-valuation growth stocks to changes in discount rates. Investors should monitor elevated valuations and short interest, which can fuel rapid moves in both directions, as well as regulatory developments affecting precision medicine and genomic data. Capital flows into thematic healthcare funds and any rotation away from innovation-heavy equities remain key swing factors. The fund's concentrated, active structure means dispersion among its top holdings will likely continue to drive overall performance.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for ARKG turns positive, indicating new upward trend
ARKG saw its Momentum Indicator move above the 0 level on August 03, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 83 similar instances where the indicator turned positive. In of the 83 cases, the stock moved higher in the following days. The odds of a move higher are at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for ARKG just turned positive on August 05, 2026. Looking at past instances where ARKG's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ARKG advanced for three days, in of 275 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 220 cases where ARKG Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for ARKG moved out of overbought territory on August 28, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 19 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARKG declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ARKG broke above its upper Bollinger Band on August 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Category Health